GlaxoSmithKline PLC ADR
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $8,409,000 | $7,629,000 | $8,618,000 | $8,547,000 |
Gross Profit | 6,143,000 | 5,754,000 | 5,961,000 | 6,289,000 |
EBITDA | 2,826,000 | 2,774,000 | 1,906,684 | 3,361,000 |
EBIT | 536,000 | 2,311,000 | 1,124,000 | 2,623,000 |
Net Income | 435,000 | 1,737,000 | 636,000 | 2,013,000 |
Net Change In Cash | 8,409,000 | 7,629,000 | 8,618,000 | 8,547,000 |
Free Cash Flow | 2,206,564 | 698,000 | 1,476,087 | 2,599,208 |
Cash | 3,086,259 | 4,538,965 | 3,391,029 | 4,437,240 |
Basic Shares | 2,031,000 | 2,037,000 | 2,043,000 | 2,051,000 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $32,667,000 | $31,376,000 | $30,328,000 | $29,324,000 |
Gross Profit | 23,650,000 | 22,328,000 | 21,763,000 | 19,770,000 |
EBITDA | 10,402,000 | 6,668,000 | 9,083,000 | 8,601,000 |
EBIT | 8,088,000 | 4,117,000 | 6,789,000 | 6,454,000 |
Net Income | 5,716,000 | 2,575,000 | 4,928,000 | 14,956,000 |
Net Change In Cash | 32,667,000 | 31,376,000 | 30,328,000 | 29,324,000 |
Free Cash Flow | 5,824,498 | 3,572,000 | 6,257,522 | 5,145,000 |
Cash | 3,391,029 | 3,693,000 | 3,742,813 | 3,723,000 |
Basic Shares | 2,058,500 | 2,071,000 | 2,055,500 | 2,042,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | $1.36 |
2026-03-31 | $1.26 |
2025-12-31 | $0.70 |
2025-09-30 | $1.46 |